AI in the Pharmaceutical Industry:
How Supply Chain Became a Strategic Frontier for the Sector

In the pharmaceutical industry, talking about supply chain has never been only about operational efficiency. Unlike other sectors, a supply disruption can mean treatment delays, unavailability of essential medicines, increased costs for healthcare systems, and direct risk to patients’ lives. That is why planning, production, quality, distribution, and compliance need to operate as a single system — not as isolated areas that only come together during the monthly S&OP cycle.

This complexity is not new, but it has become more evident in recent years. Pharmaceutical supply chains are globalized and depend on multiple suppliers, active ingredients, manufacturing plants, CMOs, regulatory approvals, quality rules, shelf-life constraints, capacity restrictions, and inventory policies that must balance working capital and service levels. According to the OECD, global trade in pharmaceutical products has grown tenfold over the last three decades and reached USD 900 billion in 2022, with intermediate inputs, such as APIs, accounting for half of the movement of goods by value. [1]

This context helps explain why the supply chain agenda is no longer just an operations topic. Today, it sits at the center of discussions around risk, growth, reputation, and business continuity.

The Challenge: Planning in a Sector Where Errors, Delays, and Excess Have Direct Impact

The pharmaceutical industry operates under constant tension. On one hand, companies need to guarantee availability, avoid stockouts, and sustain high service levels. On the other, they need to control inventory, reduce losses due to expiration, manage write-offs, and operate within strict quality and compliance standards.

This equation becomes even more difficult because many structural supply chain issues do not appear in isolation. An inaccurate forecast can lead to the wrong production decision. A demand shift can pressure a CMO’s capacity. A long lead time between plants can increase the need for safety stock. A master data failure can compromise the supply plan. A raw material delay can trigger a cascading effect across production, distribution, customer service, and revenue.

Regulatory agencies have also been reinforcing the importance of this topic. The FDA points out that drug shortages may be caused by manufacturing and quality issues, delays, and discontinuations. [2] The EMA highlights that medicine shortages can impact patient care and may result from production difficulties, quality issues, or increased demand. [3] In Brazil, Anvisa establishes rules for communicating manufacturing interruptions and provides measures such as monitoring critical cases, publishing information on discontinuations, exceptional imports, and prioritizing reviews when there is a risk of shortage. [4]

In other words: supply chain in pharma is operations, but it is also governance, traceability, risk management, and healthcare responsibility.

What Real Projects Reveal About the Sector’s Maturity

Practical experience in supply chain projects for Life Sciences shows that the most recurring challenges are not only technological. They appear in the way processes, data, and decisions are organized.

In one case involving a large pharmaceutical group with a multi-brand portfolio and multiple industrial units, the main challenges were related to long lead times between plants, complex flows of semi-finished materials, the need for integrated planning across companies, and the requirement to maintain service levels above 90%. The solution involved a Demand-Driven Replenishment process covering the end-to-end chain — from raw materials to finished goods replenishment — with a daily planning cycle and analytics on SAP BTP. The result was a 10% to 15% reduction in inventory levels, while maintaining a balance with high service levels.

In another case, a pharmaceutical company operating across multiple healthcare segments faced long planning cycles, manual processes with no ERP integration, low adherence to inventory policies, and a lack of connection between scheduling and capacity. MPS and MRP operated in silos, making decision-making more difficult. The initiative focused on optimizing Master Production Planning to Execution, integrating network planning, short-term sequencing, and production capacity. The gains included a 5% to 8% reduction in setup times, a 5% increase in productivity and resource utilization, and a 20% reduction in the S&OP cycle time.

A third case, involving a pharmaceutical company specialized in dermatological therapies and highly dependent on CMOs, revealed another critical point: the need to integrate planning, execution, and external collaboration. The challenge was to connect SAP IBP with SAP S/4HANA RISE, establish an IT-supported S&OP calendar, align Operations, Finance, and Commercial teams, reduce stockout and scrap risks, and approve forecasts and production plans from manufacturing partners. The solution involved SAP IBP S&OP, Control Tower, and integration with S/4. The expected benefits were directly linked to improved forecast accuracy, fewer stockouts, and a shorter S&OP cycle time.

These examples reveal an important conclusion: pharmaceutical supply chain transformation does not begin with automation. It begins with the ability to see, plan, and decide based on reliable data.

Where AI Is Already Being Applied in the Pharmaceutical Supply Chain

Artificial Intelligence is often treated as a future promise. But in supply chain planning, part of it has already been operating for years — especially in platforms such as SAP IBP, where statistical models, machine learning, mathematical optimization, and predictive analytics already support critical decisions.

In demand planning, AI helps identify patterns, correct outliers, interpret trend changes, incorporate internal and external drivers, and improve forecast quality. In pharma, this is especially relevant because demand can be affected by seasonality, commercial campaigns, new launches, physician behavior, institutional purchases, regulatory changes, and epidemiological events.

In inventory optimization, models move away from a flat safety stock logic and begin considering uncertainty, service level, lead time, supply variability, and the right inventory position within the network. For pharmaceutical companies, this is decisive: excess inventory can become loss due to expiration; insufficient inventory can become a shortage.

In response & supply, mathematical optimization makes it possible to evaluate supply alternatives while respecting constraints related to materials, capacity, costs, contracts, production, and distribution. In a sector with specialized plants, CMOs, batches, setups, and quality requirements, this capability reduces dependency on manual decisions and makes the plan more defensible.

In S&OP, AI supports anomaly detection, master data analysis, and the identification of inconsistencies that could compromise the consensus plan. This is especially relevant because, in pharma, incorrect data is not just an administrative error. It can distort forecasts, compromise production, generate excess inventory, or affect customer service.

Joule and the New Conversational Layer of Supply Chain

The most recent evolution lies in how users interact with systems. With the advancement of generative copilots such as Joule, AI is no longer only “behind” the algorithms; it also becomes a working interface for planners, managers, and operations teams.

In practice, this means that a user can ask questions in natural language, navigate between applications, query data, trigger jobs, analyze a planning area, compare scenarios, and understand why a forecast failed or why an inventory target was not achieved.

This conversational layer has three important impacts for the pharmaceutical industry.

The first is adoption. Many planning processes still depend on experienced planners, parallel spreadsheets, and tacit knowledge. A conversational interface reduces usage barriers and accelerates access to information.

The second is speed. Instead of searching for data across multiple dashboards, reports, and screens, users can start from a business question: “Where do we have shortage risk?”, “Which alternative supplier reduces the impact?”, “Which scenario better protects the service level?”, or “Why did the plan for this product family fall outside the inventory policy?”

The third is governance. When connected to internal documents, policies, runbooks, and verified data, the copilot can support decisions based on contextualized knowledge — not only on generic responses.

Agentic AI: From Recommendation to Orchestration

The next stage of AI in supply chain is agent-based action. In this model, AI does not only respond or recommend; it coordinates work steps, simulates alternatives, identifies risks, and proposes actions within governance-defined limits.

Imagine a disruption in a distribution center or a relevant delay from a CMO. An agent can identify the impact on customer service, simulate alternative suppliers or plants, calculate the effect on service level, evaluate capacity constraints, recommend the best scenario, and request human approval before moving forward with the order or plan adjustment.

For the pharmaceutical industry, this evolution is particularly powerful, but it must be handled carefully. Agents can support production planning, order confirmation, component shortage monitoring, inventory allocation, batch optimization, regulatory compliance, batch release, product recall, documentation, quality, and change management. But because this is a regulated sector, automation must be auditable, explainable, and controlled.

The FDA has already been discussing the use of AI in pharmaceutical development and manufacturing, including applications in process control, equipment reliability, throughput, early deviation signal monitoring, recurring pattern detection, and batch loss prevention. The agency also highlights the importance of a risk-based assessment when AI supports decisions related to safety, efficacy, or quality. [5]

This point is essential: in pharma, AI cannot be a black box operating at the margins of processes. It must be integrated into the operational core, connected to the right data, and subject to governance compatible with the risk level of each decision.

AI Does Not Fix a Poorly Designed Supply Chain

The biggest mistake companies make is not underestimating AI. It is overestimating what AI can do when processes, data, and responsibilities remain fragmented.

If the forecast is approved outside the system, if S&OP does not connect Commercial, Operations, and Finance, if CMOs work with outdated information, if master data is inconsistent, and if planning still depends on manual reconciliations, AI will have limited room to generate sustainable value.

AI needs context. It needs to know which product is critical, which customer should be prioritized, which batch expires first, which supplier is constrained, which plant has capacity, which demand is atypical, and which inventory policy must be respected. Without this context, AI may generate insights. But it will hardly sustain reliable decisions.

That is why the most mature path for the pharmaceutical industry involves five movements.

The first is to integrate data and processes end to end, connecting planning, ERP, production, quality, logistics, procurement, and external partners. The second is to structure an S&OP process truly oriented toward decision-making, with a clear calendar, roles, indicators, and rules. The third is to activate AI capabilities already available in planning, such as statistical forecasting, machine learning, inventory optimization, and constraint-based planning. The fourth is to evolve toward control towers and scenario simulations, increasing the ability to anticipate risks. The fifth is to incorporate copilots and agents gradually, with governance, traceability, and validation.

The Future of the Pharmaceutical Supply Chain Will Be More Autonomous, But Not Less Human

The direction is clear: pharmaceutical supply chains will become increasingly predictive, connected, and autonomous. But this does not mean removing people from the decision-making process. It means freeing teams from repetitive tasks, reducing time spent on reconciliations, and allowing planners, supply chain leaders, and executives to focus their energy on decisions that truly require human judgment.

AI can identify risk. It can simulate alternatives. It can explain impacts. It can recommend actions. It can execute steps within defined limits. But strategy, governance, and accountability remain human.

In the pharmaceutical industry, this combination is decisive. The sector needs more efficiency, but it cannot give up safety. It needs more automation, but it cannot lose traceability. It needs to reduce inventory, but it cannot compromise availability. It needs to accelerate decisions, but without weakening compliance.

It is within this balance that AI stops being a trend and becomes an operational capability.

For pharmaceutical companies, the question is no longer whether Artificial Intelligence will be used in the supply chain. It is already being used. The more important question now is: is the supply chain prepared — in data, processes, governance, and culture — to turn this intelligence into better, faster, and more reliable decisions?

Supporting sources used in the article:
[1] OECD — Securing Medical Supply Chains in a Post-Pandemic World
[2] FDA — Drug Shortages
[3] EMA — Medicine Shortages
[4] Anvisa — Rules and measures related to medicine shortages and manufacturing interruptions
[5] FDA — Artificial Intelligence and Machine Learning in Drug Development and Manufacturing